Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Shares Outstanding (2016 - 2025)

Immucell (ICCC) has disclosed Shares Outstanding for 16 consecutive years, with $9.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding rose 2.35% year-over-year to $9.1 million, compared with a TTM value of $9.1 million through Sep 2025, up 2.35%, and an annual FY2024 reading of $9.0 million, up 15.72% over the prior year.
  • Shares Outstanding was $9.1 million for Q3 2025 at Immucell, roughly flat from $9.1 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $9.1 million in Q2 2025 and bottomed at $67301.0 in Q2 2022.
  • Average Shares Outstanding over 5 years is $6.2 million, with a median of $7.8 million recorded in 2021.
  • The sharpest move saw Shares Outstanding tumbled 99.14% in 2022, then skyrocketed 11632.93% in 2024.
  • Year by year, Shares Outstanding stood at $7.8 million in 2021, then changed by 0.0% to $7.8 million in 2022, then changed by 0.0% to $7.8 million in 2023, then grew by 15.72% to $9.0 million in 2024, then rose by 0.7% to $9.1 million in 2025.
  • Business Quant data shows Shares Outstanding for ICCC at $9.1 million in Q3 2025, $9.1 million in Q2 2025, and $9.0 million in Q4 2024.